CandlesenseCandlesense
News/Companies/INKT

INKT News

MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease

INKT

NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering off-the-shelf allogeneic invariant natural killer T (allo-iNKT) cell therapies, today announced the upcoming initiation of a Phase 1, investigator-sponsored clinical trial evaluating its lead therapy, agenT-797, in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

January 8, 2026
Read more →

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

INKT

NEW YORK, Aug. 14, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced financial results for the second quarter ended June 30, 2025, and provided a business update highlighting major clinical achievements, a strengthened balance sheet, and expanded funding to advance both oncology and immunology programs.

August 14, 2025Earnings
Read more →

MiNK Therapeutics Awarded Grant From NIAID To Support Development Of MiNK's Allo- iNKT Cell Therapy Platform For Prevention And Treatment Of GvHD

INKT

June 2, 2025
Read more →

HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $35 Price Target

INKT

March 18, 2025
Read more →

MiNK Therapeutics Q4 2024 GAAP EPS $(0.62) Misses $(0.50) Estimate

INKT

March 18, 2025
Read more →

HC Wainwright & Co. Maintains Buy on MiNK Therapeutics, Raises Price Target to $35

INKT

February 25, 2025
Read more →

MiNK Therapeutics Announces New Phase 2 Data For Allo-iNKTs At AACR IO Annual Meeting; Study Involves agenT-797 Combined With BOT/BAL For Refractory Gastroesophageal Cancer

INKT

February 24, 2025
Read more →

MiNK Therapeutics Says It Now Meets All Nasdaq Capital Market Listing Requirements, Regains Compliance

INKT

February 20, 2025
Read more →

MiNK Therapeutics To Present Updated Data From Phase 2 Study Testing AgenT-797 In Gastric Cancer At AACR IO Annual Meeting

INKT

February 12, 2025
Read more →

Baird Maintains Outperform on MiNK Therapeutics, Lowers Price Target to $4

INKT

November 15, 2024
Read more →

HC Wainwright & Co. Reiterates Buy on MiNK Therapeutics, Maintains $9 Price Target

INKT

November 15, 2024
Read more →

MiNK Therapeutics Q3 EPS $(0.05) Beats $(0.08) Estimate

INKT

November 14, 2024
Read more →

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient With Severe Acute Respiratory Distress At ATS Annual Meeting

INKT

May 22, 2024
Read more →